Meclofenamic acid is a balanced COX-1/COX-2 inhibitor and a non-selective gap junction blocker.

GAP-134, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.

GAP-134 HCl, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.

Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state.

Gap 26, a mimetic peptide of connexin, is the gap junction blocker that corresponds to the residues 63-75 of connexin 43.

Gap 27 is peptide derived from connexin 43 that is a selective gap junction blocker. 

Tonabersat is a gap-junction modulator.